CURE1d
Surviving Life-Threatening Lung Cancer: Lessons Learned
Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling. My life has changed ...
CURE13d
Datroway May Be Effective in Non-Small Cell Lung Cancer Subtypes
Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic ...
Memorial Sloan Kettering Cancer Center2d
How One Young Adult With Stage 4 Lung Cancer Is Beating the Odds
Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...
Medindia1d
Lung Cancer in Nonsmokers, Why Women Are at Risk?
Lung Cancer in Non-Smokers: Clinicopathological and Survival Differences from Smokers - ...
Managed Healthcare Executive7d
Study Explores Immunotherapy vs. Chemoimmunotherapy Decisions For Advanced Non-Small Lung Cancer
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
Medpage Today on MSN13d
Novel Drug Shrinks 73% of HER2-Mutant Lung Cancers
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...
The Pharma Letter5d
MHRA backs Lazcluze combo for non-small cell lung cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Lazcluze (lazertinib) for adults with non-small ...
Crain's New York Business9d
Midtown biotech raises $250M to bring lung cancer therapy to market
Life science firm Nuvation Bio raised $250 million to bring its novel lung cancer therapy to market and help it reach ...
Business Wire2d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications ...